ABEO
ABEONA THERAPEUTICS INC.
NASDAQ · Healthcare · Biotechnology · US
$4.41
−0.45%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$4.47
From 52W high−40.88%
Volume986049.00
Market cap$252.18M
P/E (TTM)—
P/S (TTM)9.9x
Div yield—
Key dataOct 19, 2026
Open
$4.47
From 52W high
−40.88%
Volume
986049.00
Market cap
$252.18M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
P/E (TTM)
—
RSI (14)
30.1
MomentumView details →
1D Return
−0.45%
YTD Return
−16.79%
SummaryUpdated Jun 1, 2026
Abeona Therapeutics Inc. (NASDAQ:ABEO) is a clinical-stage biopharmaceutical company founded in 1974 and headquartered in New York, New York. Originally incorporated as PlasmaTech Biopharmaceuticals, the company changed its name to Abeona Therapeutics in June 2015. The company specializes in developing gene and cell therapies for life-threatening rare genetic diseases. In April 2025, Abeona achieved a major milestone with the FDA approval of <b>ZEVASKYN</b>, marking the first autologous cell-based gene therapy approved for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder.
Similar companies
Latest newsMore news →
The U.S. FDA approved a drug that Abeona Therapeutics had licensed away, entitling Abeona to collect royalties.31d agoAbeona Therapeutics activated University of Florida Health in Gainesville, Florida as the eighth Qualified Treatment Center for administering its ZEVASKYN gene-modified cellular sheets.33d ago